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 FOREWORD 
 
The Trent Working Group on Acute Purchasing was set up to enable purchasers to share 
research knowledge about the effectiveness and cost-effectiveness of acute service 
interventions and determine collectively their purchasing policy. The Group is facilitated by 
The School of Health and Related Research (ScHARR), part of the Trent Institute for Health 
Services Research, the ScHARR Support Team being led by Professor Ron Akehurst and 
Dr Nick Payne, Consultant Senior Lecturer in Public Health Medicine. 
 
The process employed operates as follows. A list of topics for consideration by the Group is 
recommended by the purchasing authorities in Trent and approved by the Health Authority 
And Trust Chief Executives (HATCH) and the Trent Development and Evaluation Committee 
(DEC). A public health consultant from a purchasing authority leads on each topic assisted 
by a support team from ScHARR, which provides help including literature searching, health 
economics and modelling. A seminar is led by the public health consultant on the particular 
intervention where purchasers and provider clinicians consider research evidence and agree 
provisional recommendations on purchasing policy. The guidance emanating from the 
seminars is reflected in this series of Guidance Notes which have been reviewed by the 
Trent DEC, chaired by Professor Sir David Hull. 
 
In order to share this work on reviewing the effectiveness and cost-effectiveness of clinical 
interventions, The Trent Institute’s Working Group on Acute Purchasing has joined a wider 
collaboration, InterTASC, with units in other regions. These are: The Wessex Institute for 
Health Research and Development and The University of Birmingham Department of Public 
Health and Epidemiology. 
 
 
 
 
 
 
 
Professor R L Akehurst 
Chairman, Trent Working Group on Acute Purchasing 
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EXECUTIVE SUMMARY 
 
Description of the proposed service: Endoluminal repair of abdominal aortic aneurysm 
(AAA) instead of open surgical repair. 
 
Epidemiology: Prevalence of aneurysms >49mm in diameter is estimated at around 120 
per 100,000 in the age group 50-79. AAAs are more common in males and prevalence 
increases at older ages. 
 
Number and quality of studies and direction of evidence: No randomised controlled 
trials, but eight non-randomised controlled studies were found. A total of 481 patients had 
endoluminal repair and 472 ('controls') had open repair in these studies. Four studies 
suggested that endoluminal repair had a lower rate of systemic/remote complications than 
open repair, but in three of these there was a higher rate of local/vascular complications. 
Peri-operative mortality was similar, although mostly lower with endoluminal repair. The 
overall success rate of endoluminal repair was between 70-80% (i.e. successful placement, 
no endoleak and without mortality by 30 days). Long-term outcome studies were not 
available. 
 
A UK Endovascular Aneurysm Repair (EVAR)1 randomised controlled trial will compare 
endovascular with open repair in patients suitable for either procedure. The results from the 
UK small aneurysm trial did not support a policy of open repair for AAAs of 40-55mm in 
diameter – whether this policy should alter, if endoluminal repair replaced open repair, is not 
clear from the published evidence. A second Endovascular Aneurysm Repair (EVAR2) trial 
will compare endovascular repair with a ‘watch and wait’ policy for patients unfit for open 
repair. 
 
Costs: Estimates of costs for endoluminal repair vary from 14% less, to 20% more, than for 
open repair. Costs are very sensitive to Intensive Therapy Unit (ITU) utilisation. Cost 
estimates using information from one hospital in Trent (Northern General Hospital, Sheffield) 
suggest costs of treating fit patients of £7,500 for endoluminal repair and £6,300 for open 
repair.  The costs of an endoluminal repair for unfit patients are higher due to a longer 
hospital stay and are estimated at £8,300. Emergency open repair of ruptured AAA has 
been estimated to cost up to £13,000. 
 
 2 
Cost-effectiveness and cost-utility: No papers were found reporting formal cost-
effectiveness or cost-utility. The lack of published evidence on long-term outcome prevents 
the calculation of life years gained or cost per life year gained. A decision analysis modelling 
approach could be used to generate initial estimates of cost-effectiveness and to identify 
threshold values for key variables. Some work in this area is in progress in Sheffield. During 
the final drafting of this report, early results from the Sheffield work analysing the unfit and 
the unsuitable for open repair patient groups, indicate that endoluminal repair is likely to be 
cost-effective for both groups.  The EVAR trials in the UK may help to validate the current 
modelling work. 
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ABBREVIATIONS 
 
AAA Abdominal Aortic Aneurysm 
ACOST Advisory Committee on Science and Technology 
CT Computed Tomography 
ER Endoluminal Repair 
EVAR Endovascular Aneurysm Repair 
HDU High Dependency Unit 
ITU Intensive Therapy Unit 
ODA Operating Department Assistant 
QALY Quality Adjusted Life Year 
RETA Registry for Endovascular Treatment of Aneurysms 
SERNIP Safety and Efficacy Register of New Interventional Procedures (of 
the Academy of Medical Royal Colleges) 
UKSAT UK Small Aneurysm Trial 
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1. INTRODUCTORY REMARKS  
 
Abdominal aortic aneurysms (AAA)s are swellings of the wall of the main descending artery 
in the abdomen. Untreated, these aneurysms are likely eventually to leak or rupture; an 
event which, even if surgically treated, carries a high mortality. At present, AAAs are 
repaired by open abdominal surgery. The new procedure discussed in this report uses a 
synthetic graft introduced through an artery; it is a less invasive procedure, similar to other 
'keyhole' surgery in its implications. This report assesses the evidence for the effectiveness 
of this new procedure and its impact on costs, including possible changes in treatment 
thresholds. 
 
2. DESCRIPTION OF UNDERLYING DISEASE   
 
2.1  Epidemiology (incidence and/or prevalence in an average health authority of 
500,000 population
a
) 
 
Recent population screening surveys, using ultrasonic examination of the aorta, have 
provided the best estimates of the prevalence of AAAs. The surveys are not all exactly 
comparable either in terms of the definitions used (i.e. the diameter of the aorta) or the age 
bands. However, there is general agreement. As with other vascular degenerative diseases, 
AAAs are more common in men than women and the number increases with age. 
 
The prevalence of small AAAs in elderly men in England depends upon the age group 
screened and the criteria used for the definition of AAA. 1.3% of the male population aged 
50 and over appears to have an AAA when this is defined as an aorta of 46mm or wider, 
and as many as 5.2% have an AAA using a definition of an aorta wider than 29mm.
1
 AAAs 
are less common in women than in men; the Chichester screening survey found that only 
1.3% of women aged between 65 and 80 had an aorta wider than 29mm, compared with 
7.6% of men in the same age group (see Table 1). 
 
                                            
a
 Age structure as per England and Wales 
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Table 1 Prevalence of Abdominal Aortic Aneurysms in the General Population found by Screening Surveys in the UK 
   
Location Authors Aortic diameter Sex Age 
(years) 
Number of 
Patients 
Screened 
Prevalence  
Oxford Collin et al. 1988
2
 5mm greater than the 
diameter of the 
suprarenal aorta 
MALE 65-74  426 5.4% 
Northumberland Holdsworth 1994
3
 >49mm MALE 65-79  628 1.6% 
Huntingdon Morris et al. 1994
1
 > 46mm MALE > 50  3,030 1.3% 
Oxford Collin et al. 1988
2
 >40mm MALE 65-74  426 2.3% 
Oxford Collin et al. 1990
4
 >40mm MALE 65-74  746 2.0% 
Gloucestershire Lucarotti et al. 1993
5
 >40mm MALE 65  4,232 1.3% 
Birmingham Smith et al. 1993
6
 >40mm MALE 65-75  2,669 3.0% 
Liverpool Loh et al. 1989
7
 >30mm MALE > 55  657 2.9% 
Huntingdon Morris et al. 1994
1
 > 30mm MALE > 50  3,030 5.2% 
Birmingham Smith et al. 1993
6
 >29mm MALE 65-75  2,669 8.4% 
Chichester Scott et al. 1995
8
 >29mm MALE 65-80  2,342 7.6% 
   FEMALE 65-80  3,052 1.3% 
Northumberland Holdsworth 1994
3
 >29mm MALE 65-79  628 6.7% 
Huntingdon Wilmink et al. 1998
9
 >29mm MALE > 50  7,493 5.2% 
Gloucestershire Lucarotti et al. 1993
5
 >25mm MALE 65  4,232 8.4% 
Oxford Collin et al. 1990
4
 >25mm MALE 65-74  746 6.3% 
Chichester Khoo et al. 1994
10
 Unspecified MALE 65-80  6,078 6.8% 
   FEMALE 65-80  5,588 1.2% 
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Two studies suggest that around 5% of elderly men have an aortic diameter of 
25-39mm.
4,5
 Whilst an aorta below 30mm in diameter would not strictly be defined as 
an aneurysm, it has been suggested that, because the behaviour of aortas with 
diameters between 26 and 40mm is unpredictable, patients with an aortic diameter 
greater than 25mm should be followed up with annual ultrasonographic scans and 
referred for surgical assessment should the diameter reach 40mm.
11
 
 
The prevalence of AAA increases steeply with age. Table 2 presents data from those 
surveys which divided their subjects into age bands. One survey found that, whilst 
only 0.3% of men aged between 50 and 64 appeared to have an aorta of 46mm or 
wider, this figure rose to 4.1% of men aged 80 and over, an almost fourteen-fold 
increase. 2.3% of men aged between 50 and 64 appeared to have an aorta of 30mm 
or wider, compared with 11.9% of men aged 80 years and over.
1
 
 
Although the prevalence of AAA is substantially lower in women than in men, in 
women too the prevalence increases markedly with age. One study found that 1.7% 
of women aged between 71 and 80 had an aorta wider than 29mm, compared with 
0.8% of those aged 65 and 70,
8
 whilst another found that the prevalence rose from a 
rate of 0.6% in women aged between 65 and 67 to peak at 2.4% in women aged 
between 74 and 76.
10
 
 
The prevalence of screen-detected AAA in the UK is very similar to that in other 
countries in the Western world.
9
 
 
The UK Small Aneurysm Trial (UKSAT)
12
 has now indicated that there is no overall 
benefit in performing open repairs in aneurysms of 55mm and under. The nearest 
prevalence data to such a figure is from the Northumberland survey,
3
 which reported 
AAAs greater than 49mm in 65-79 year old men at a prevalence of 1.6%. A 
male/female ratio of about 6:1 in this age group was recorded in other studies
8,10
 
and, although this was not specifically at the size of greater than 49mm, this gives 
the best available estimate of the prevalence of these larger AAAs in women. The 
Huntingdon survey
1
 gives a ratio for 50-64 years of age to 65-79 years of 1:8 in men 
for AAAs greater than, or equal to, 46mm, which would imply a rate of AAAs greater 
than 49mm amongst 50-64 year olds of less than 0.2% for men and 0.03% for 
women. Thus, Table 3 gives an indication of prevalence of aneurysms of greater 
 7 
than 49mm for an average English health authority and primary care group 
populations. 
 8 
Table 2 Prevalence of Abdominal Aortic Aneurysms in the General Population found by Screening Surveys in the UK, by Age 
 
Location Authors Aortic 
Diameter 
Sex Age (years) Number of 
Patients 
Prevalence 
Huntingdon Morris et al. 1994
1
 > 46mm Male 50-64  1,776  0.3% 
    65-79  1,061  2.5% 
    > 80  193  4.1% 
Liverpool Loh et al. 1989
7
 >30mm Male 55-64 Not stated  1.3% 
    > 65 Not stated  6.5% 
Huntingdon Morris et al. 1994
1
 > 30mm Male 50-64  1,776  2.3% 
    65-79  1,061  8.8% 
     > 80  193  11.9% 
Chichester Scott et al. 1995
8
 >29mm Male 65-70  1,091  5.9% 
    71-80  1,251  9.1% 
   Female 65-70  1,341  0.8% 
    71-80  1,711  1.7% 
Chichester Khoo et al. 1994
10
 unspecified Male 65-67  2,830  5.4% 
    68-70  1,520  7.0% 
    71-73  602  9.6% 
    74-76  560  8.6% 
    77-79  471  10.4% 
    80  95  1.1% 
   Female 65-67  2,438  0.6% 
    68-70  930  1.3% 
    71-73  711  1.3% 
    74-76  718  2.4% 
    77-79  632  2.1% 
    80  159  0.6% 
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Table 3 Estimated Prevalence of Abdominal Aortic Aneurysms >49mm in 
Populations of 100,000 and 500,000 
 
Age 
(years) 
%  
Male 
% 
Female 
Males/ 
100,000 
population 
Females/ 
100,000 
population 
Total for 
100,000 
population 
Total for 
500,000 
population 
50-64 0.2 0.03 16  3   18   91 
65-79 1.6 0.27 83 18 101 504 
50-79   99 20 119 595 
 
 
On the basis of re-screening 682 men with normal initial scans, one study has 
calculated that, between the ages of 65 and 70, new cases develop at a rate of 3.7% 
over five years.
10
  Whilst this represents an annual incidence of 0.75% for this age 
group, it is difficult to use this figure to estimate for the entire population, especially 
as this paper did not indicate the threshold size of aneurysm. Current activity in Trent 
suggests that rates of admission for AAA are 7.7 per 100,000 and 7.3 per 100,000 
per annum for elective and emergency admissions respectively.
13
 In a 'typical' district 
of 500,000 residents, therefore, 38 elective and 36 emergency AAA admissions 
respectively can be expected per annum.      
 
2.2  Pathology and Prognosis 
Aortic aneurysm has also been defined as a focal dilatation of the aorta involving an 
increase in diameter of at least 50% compared with the expected normal diameter
14
 
or, in the case of AAA, a luminal diameter greater than 30mm.
15
  89% of all 
abdominal aneurysms affect the infrarenal aorta.
15
 
 
The best predictor of AAA development is a positive family history of the condition.
16
 
As has been seen, advancing age is also an important factor. Population-based 
screening surveys show that male sex and smoking are also important risk factors 
(relative risk 6.5 and 2.9 respectively). These surveys also indicate that patients with 
peripheral vascular disease and cardiovascular disease are twice as likely to have an 
AAA as those without those diseases. Hypertension is associated with a mildly 
increased risk of AAA (relative risk 1.5), but diabetes and hypercholesterolaemia are 
not associated with an increased risk.
9
 
 
For technical and ethical reasons, the natural history of AAAs has not been precisely 
determined.
16
  However, it is clear that untreated aneurysms are likely to expand 
and, eventually, rupture, although the rates of expansion and frequency of rupture 
 10 
are unpredictable. 25 to 41% of aneurysms larger than 50mm in diameter rupture 
within five years, and aneurysms of 40-50mm in diameter, have been reported to 
have five-year rupture rates of 3 to 12%, although data relating to these smaller 
aneurysms are sparse.
14
   
 
Up to 62% of patients with ruptured aneurysms die before reaching hospital.
17
  When 
these pre-hospital deaths are combined with the mortality rate of approximately 50% 
associated with repair of ruptured AAAs, the overall mortality rate after rupture may 
exceed 80%.
14
 Moreover, the quality of life declines after emergency repair for 
rupture.
18
 The urgent repair of symptomatic, unruptured AAAs is also associated with 
increased mortality and high morbidity in comparison with elective aneurysm repair.
19
 
 
Most deaths due to rupture are potentially preventable by elective repair of the AAA. 
However, it is not clear at what point that repair should, ideally, be undertaken. It has 
been argued on the one hand that elective surgery is inappropriate for aneurysms 
under 50mm in diameter because the rupture rate is negligible and would be 
outweighed by the risks associated with the intervention.
20
 This view is supported in 
respect of open repair by the UKSAT results.
12
 On the other hand, some argue that 
early surgery would generally improve survival in patients with AAAs less than 50mm 
in diameter, although watchful waiting is generally preferable for those with AAAs 
less than 40mm in diameter.
21
 The debate will not be resolved fully until the results 
are available from the three ongoing multicentre trials which seek to identify 
appropriate criteria for the elective repair of small AAAs.
22
  However, it is clear that, 
because of the dramatic increase in rupture risk for AAAs larger than 50-60mm, 
nearly all patients with an AAA of this size benefit from elective repair, unless the 
operative risk is very high.
21
 
 
2.3  Significance in Terms of Ill-Health (Burden of Disease) 
2.3.1 Asymptomatic AAA 
80% of AAAs are asymptomatic and are only detected either by imaging studies 
done for other reasons,
16
 or after death.
2
 Therefore, accurate information on the 
incidence of asymptomatic AAA is difficult to obtain. Reported incidences vary 
between 3.0 and 117.2 per 100,000 per annum.
9
  
 
All studies report sharp rises (from 4.2 to 11% per year) in the age-adjusted 
incidence of AAA in recent years. However, as incidence rates have generally been 
 11 
estimated on the basis of the number of hospital admissions for elective repair of 
asymptomatic aneurysms, this apparent rise may be due, at least in part, to 
increased case finding resulting from the increased use of ultrasonography.
9
 
 
2.3.2 Ruptured AAA 
Ruptured AAA is extremely uncommon before the age of 55.
5
 However, although 
death from ruptured AAA is rare before the age of 50, it becomes increasingly 
common in men over the age of 55.
2
 1.36% of deaths in men and 0.45% of deaths in 
women over the age of 65 in England and Wales are due to this cause.
9
  Its greatest 
impact is in men aged 70-74 years, among whom it accounts for 1.8% of all deaths. 
Ruptured AAA is much less common in women under the age of 80 and, at its peak, 
accounts for 0.6% of all deaths in women aged 80-84.
2
 
 
The recent reported incidence of ruptured AAA varies from 1 to 21 per 100,000 per 
annum. The Goteborg study
23
 found a sevenfold rise in incidence over a 36-year 
period, and this was not entirely due to an ageing population as the age-
standardised mortality rate of ruptured AAA also rose by 2.4% per year. However, 
the reported rise in incidence may be due in part to an increased level of reporting 
caused by an increased awareness of the condition.
9
 
 
 12 
3.  CURRENT SERVICE PROVISION  
 
There is as yet little evidence of an effective medical treatment for AAA, although 
randomised controlled trials of propranolol in patients with small aneurysms are 
underway.
9
 Currently, therefore, the only intervention known to prevent ruptured 
aneurysm is elective repair of asymptomatic lesions over a certain size. Until 
recently, open repair has been the only alternative to conservative treatment.  
 
3.1  Open Repair 
 
To prevent rupture, surgical treatment has been recommended for all symptomatic 
AAAs, and for asymptomatic aneurysms larger than 55mm in diameter, provided that 
such treatment is not precluded by coexisting conditions.
14
  It was also suggested 
that early surgery was preferable to expectant observation for all aneurysms 
between 40-50mm in diameter, unless they are in patients who are at increased 
surgical risk and at low risk for acute aneurysm expansion.
21
 However, as discussed 
earlier, the UKSAT
12
 has recently reported no advantage in terms of mortality rates 
in a policy of open elective surgery compared with ultrasonic surveillance for those 
with aneurysms of 40-55mm in diameter. It was concluded that  'our results do not 
support a policy of open surgical repair for abdominal aortic aneurysms of 40-55mm 
in diameter'. Absence of reliable data on aneurysm expansion rates makes it hard to 
determine whether there are sub-groups of patients with smaller aneurysms which 
might benefit more from early surgery.
24
  
 
Open surgery for AAA has been carried out since the fifties. Mortality after such 
surgery usually lies between 2-7%,
19
 and post-operative complications, which occur 
on average 3-5 years after aortic reconstruction, may increase the overall mortality 
rate by a further 2%.
18
 Other disadvantages of open surgery include lengthy hospital 
stays, post-operative pain and the possibility of sexual dysfunction.
19
  However, the 
quality of life after elective repair is good.
18
 
 
In patients over 75 years of age, peri-operative mortality for open repair exceeds 
20%, even for elective procedures. The most important risk factors in these patients 
are severe cardiac, renal and pulmonary disorders and morbid obesity.
15
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3.2   Conservative Treatment 
 
Conservative treatment may imply one of the following options: 
 
 no treatment (for patients unfit to survive any intervention, or who appear, 
because of other conditions, such as, malignant disease, to have only a short 
time for survival following intervention); 
 intervention only on an emergency basis (for patients who are unfit for elective 
surgical treatment, but may be operated on in case of rupture); 
 expectant observation of small AAAs ('watchful waiting').
19
 
 
Conservative treatment also requires adequate management of hypertension and 
other risk factors, such as, elevated lipids, and advice and help in respect of smoking 
cessation.  
 
3.2.1 Current Service Cost 
The current costs of treating AAAs in an average health authority are crudely 
estimated at £650,000 per annum. 
 
3.2.2 Variation in Services 
Examination of data from the Trent Regional Patient Information System proved 
problematic, with obvious differences in coding policies between units distorting any 
genuine variations.  
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4. DESCRIPTION OF NEW INTERVENTION  
 
4.1 Information on the Proposed Service 
 
Endoluminal repair (ER) is a relatively recent procedure, first performed in 1990. It 
uses minimally invasive techniques to exclude the aneurysm sac from the arterial 
circulation by placing, within the aortic lumen, a prosthetic graft inserted from a 
remote site and fixed in position using expandable wire stents or hook systems 
rather than sutures. Currently two technologies dominate stent design: self-
expanding stents and those requiring expansion by a balloon once in place. One 
type of device, the aorto-uni-iliac device has to be accompanied by an open 
procedure to 'crossover' a blood supply to the contra-lateral iliac artery; this is a 
relatively minor open procedure and can be performed under local anaesthetic in 
suitable cases. 
 
4.2 Identification of Patients and Important Sub-groups 
 
Because it is less invasive than open repair, ER can reduce the length of hospital 
stay, and it has been suggested that it is particularly of value in elderly patients and 
those at high risk from open surgery. As a result, its use has been reported in 
patients over 80 years of age or with a history of cardiac disease, respiratory 
disease, end stage chronic renal failure, 'hostile abdomen' (that is, an abdomen 
affected by extensive scarring or adhesions between organs, that makes surgery 
within the abdominal cavity difficult and hazardous), haematological abnormalities or 
previous cerebrovascular accident.
25
 
 
4.3 Criteria for Treatment 
 
Because currently available devices demand precise pre-operative imaging, ER is of 
little value in cases of rupture.
24
 Therefore, it has been used largely for elective 
repair, although it has also been used successfully on leaking aneurysms.
26
 
 
For anatomical reasons, not all AAAs are suitable for ER. Different categories of 
stent-graft have been developed to accommodate differences in aneurysm location; 
within these categories, there is some variation in the method of attaching the device 
within the aortic lumen.
24
 For safe attachment, all three grafts generally require at 
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least 15mm of normal aorta below the renal arteries.
20
 In addition, the aorto-aortic 
tube graft requires a segment of normal aorta below the aneurysm. The aorto-bi-iliac 
(bifurcated) graft requires two common iliac arteries of sufficient calibre and length to 
receive the distal stents, while the aorto-uni-iliac graft requires only one adequate 
common iliac artery.
27
 In addition, most reported delivery systems require the aortic 
neck to have a diameter no greater than 26mm, although some systems may 
accommodate grafts suitable for use in vessels up to 30mm in diameter. The iliac 
vessels must be at least 7-9mm in diameter.
24
 Other factors which must be taken 
into consideration when assessing suitability for ER include concomitant vascular 
disease, iliac kinking or tortuosity, and iliac, renal or visceral occlusive disease.
28,29
 
Pre-operative assessment/selection is a crucial element of this intervention. 
 
4.4 Personnel Involved 
 
The procedure is performed by an Interventional Radiologist, a Vascular Surgeon, 
and Anaesthetist, with support of radiographic, Operating Department Assistant 
(ODA), and nursing staff. 
 
4.5 Setting 
 
The endovascular procedure is carried out in an operating theatre or radiological 
suite (with immediate access to a theatre when emergency conversion to open 
procedure is required), or in a dedicated endovascular theatre, usually in the 
radiology department with radiological equipment and full theatre level facilities. This 
allows a combined surgical/radiological approach without compromise of either 
speciality's facilities. 
 
4.6 Equipment Required 
 
There are a variety of stent devices currently in use. There are three basic 
anatomical types of stent (tube, aorto-uni-iliac and aorto-bi-iliac), and different 
designs/ manufacturers of each resulting in a total of 12 forms in use in the UK. Of 
these, nine are commercially available devices. Some are custom-made for each 
patient, whilst others come in standard 'off the shelf' sizes. Some other devices, (all 
aorto-uni-iliac in configuration) are the so-called 'home made' devices, which are 
constructed at the time of procedure from balloon expandable or self expanding 
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stents and surgical graft material. Information about the use of stents is now 
collected by the Registry of Endovascular Treatment of Aneurysms – RETA
b
). 
 
High quality imaging equipment is required, and in some units there is increasing use 
of computer-aided design software to help with interpretation of spiral computed 
tomography (CT) imaging and sizing of the device to match the individual patient's 
anatomy. 
 
4.7  Length of Treatment 
 
Average operating times are similar for ER and open repair, whilst in-patient stays 
(both Intensive Treatment Unit (ITU) and ward) are likely to be shorter once research 
and/or ethically driven demands for intense monitoring during trials are no longer 
necessary. 
 
4.8 Follow-up Required 
 
The length of follow-up for ER is currently distorted by the need to monitor an 
experimental procedure. 
 
4.9 Degree of Diffusion 
 
In 1996, 1997 and 1998, 14, 23 and 26 centres respectively reported to the RETA. 
There have been a total of 30 centres reporting cases to RETA between 1996 and 
1998; four reported no cases in 1998, having done so in previous years, but this 
does not mean that there was no activity at those centres. University Hospital, 
Nottingham has reported the largest series of 112 cases, and centres in the Trent 
region have reported 30% of registered cases in the UK. 15 centres (50%) have 
each registered more than 10 cases over the three years. 
 
There were three more types of stent recognised by RETA at the end of 1998 (12) 
compared to 1997 (9). 
 
                                            
b
 Third Report on the Registry for Endovascular Treatment of Aneurysms – prepared on 
behalf of the Joint Working Party of the Vascular Surgical Society of Great Britain and Ireland 
and the British Society of Interventional Radiologists, 1999. 
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4.10 Anticipated Disbenefits 
 
Problems associated with ER include post-operative dilatation of the neck of the 
aneurysm leading to stent migration, endoleaks which may lead to early aneurysmal 
rupture,
19
 macro- or micro-embolic events, renal dysfunction and intestinal 
infarction.
18
  Reported mortality associated with the procedure ranges from 0-13%, 
depending on the characteristics of the patients involved. In addition, some patients 
will need urgent conversion to open repair, and this may involve modifications to the 
standard open technique, which result in a higher than average morbidity and 
mortality rate.
19
 
 
The high rate of early complications following ER includes complications exclusive to 
endoluminal surgery:- post-implantation pyrexia; injury to common femoral or iliac 
arteries; groin wound complications; and renal impairment which may result from the 
administration of large quantities of intravenous contrast agent. It has been 
suggested that complications which are common to both endoluminal and 
conventional repair generally have a similar incidence regardless of method, but that 
the overall incidence of peripheral embolic events following endoluminal surgery is 
less than that described for conventional repair.
24
 
 
Most late complications of ER can be attributed to the development of endoleaks, 
defined as the persistence of blood flow outside the graft lumen, but within the 
aneurysm sac or adjacent vessels in which the graft is deployed. Endoleakage is a 
complication exclusive to ER. Late endoleaks can occur as a result of failure of the 
proximal or distal attachment device to remain in close apposition to the vessel wall 
or, with modular devices, the disruption of the contra-lateral limb, the so called 
'stump dislocation'. This may be due either to inappropriate patient selection, leading 
to the deployment of endoluminal devices in less than ideal aneurysm morphology, 
or to malpositioning of the device.
24
 Another contributor, particularly to stump 
dislocation, is changes in the morphology of the aneurysm after treatment. This can 
result in shortening and kinking of the main body of the device. 
 
Although long-term results are not yet available, it has been suggested that, as the 
technology improves, ER will offer the potential for lower morbidity and mortality, and 
cost savings, in comparison with open repair.
19
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4.11  Suitability of Abdominal Aortic Aneurysms for Endoluminal Repair 
 
A number of studies have attempted to assess the proportion of patients who are 
suitable for ER. The results of the relevant studies, which have been published in 
English, are set out in Table 4. As may be seen, estimates of suitability range widely 
between 9% and 66%. The lowest figures come from studies which pre-dated the 
production of a reliable, commercially available, bifurcated graft and, therefore, only 
assessed suitability for tube grafts; their authors felt that, were a reliable bifurcated 
graft available, over 50%
30
 to as many as 73%
31
 of the patients would have been 
suitable for ER. Later studies, which also assessed suitability for bifurcated or aorto-
uni-iliac grafts, suggest that these estimates were perhaps slightly optimistic. 
 
The authors of one study, which compares the suitability for ER of aneurysms of 
different size, suggest that, because aneurysms over 70mm in diameter have 
significantly wider and shorter necks than smaller aneurysms, they are less suitable 
for ER. Nonetheless, such repair appears to be feasible in 38% of these larger 
aneurysms.
32
 
 
Although the use of more complex techniques has allowed ER to be used in patients 
anatomically unsuited to tube or bifurcated grafts, it has been suggested that the 
stress involved in the lengthy procedures required may be no less than that of 
standard open surgery.
20
 
 
Not all patients have aneurysms suitable for ER; currently, at least 45% of patients 
appear to fall into this category. Estimating the proportion of patients with AAAs 
suitable for ER is problematic, especially since the publication of UKSAT.
12
 The 
survey which comes closest to the >55mm size of UKSAT,
33
 has just 110 patients 
and has the highest proportion suitable of all the surveys. Any future study of the use 
of ER of small aneurysms would need to enable sub-group analysis by size of 
aneurysm, so as to establish the treatment threshold; only then can an estimate of 
subsequent activity be attempted. 
 
RETA indicates that about 20% of cases were unfit, and about 8% fit, but unsuitable 
for conventional open repair, suggesting that, if selection criteria currently in use 
were applied to a new service, total aneurysm repair activity might increase 
significantly. 
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Table 4 Suitability for Endoluminal Repair 
 
Authors & 
Publication 
Date 
Number 
of 
Patients 
Type of Patient 
Assessed 
% Suitable 
for Tube 
Graft 
% Suitable 
for 
Bifurcated 
Graft 
% Suitable 
for Aorto-
uni-iliac 
Graft 
% Suitable 
for Graft - 
Type 
Unspecified 
% Suitable 
for any 
form of 
Stent Graft 
Andrews et al. 
1995
31
 
44 Patients admitted for 
elective AAA repair 
 9% 
 (n=4) 
- - -  9% 
 (n=4) 
Moore 1995
30
 69 Patients with a 
diagnosis of AAA 
 14% 
 (n=10) 
- - -  14% 
 (n=10) 
Collin 1995
20
 - Patients with clinically 
significant AAA 
 10% 
(n not stated) 
 15% 
(n not stated) 
- -  25% 
(n not 
stated) 
Lepantalo et al. 
1997
34
 
63 Patients with AAA > 
4mm 
- - -  27% 
 (n=17) 
 27% 
 (n=17) 
Schumacher et 
al. 1996
28
 
194 Patients admitted for 
elective AAA repair 
- - -  29% 
 (n=56) 
 29% 
 (n=56) 
Schumacher et 
al. 1997
29
 
242 Patients admitted for 
elective AAA repair 
- - -  30% 
 (n=242) 
 30% 
 (n=242) 
Moritz et al. 
1996
15
 
77 Patients with infrarenal 
AAA 
 14% 
 (n=11) 
 29% 
 (n=22) 
- -  43% 
 (n=33) 
Armon et al. 
1997
32
 
154 Patients with AAA 
larger than 45mm 
 4% 
 (n=6) 
 10% 
 (n=15) 
 55% 
 (n=85)* 
-  55% 
 (n=85) 
Armon et al. 
1997
35
 
44 Patients with AAA 45-
54mm in diameter 
   57% 
 (n=25) 
  57% 
 (n=25) 
Armon et al. 
1997
35
 
65 Patients with AAA 55-
69mm in diameter 
   66% 
 (n=43) 
  66% 
 (n=43) 
Armon et al. 
1997
35
 
45 Patients with AAA 
>70mm in diameter 
   38% 
 (n=17) 
  38%  
 (n=17) 
 
* This figure includes those patients found to be suitable for a tube or bifurcated graft, as they were also suitable for an aorto-uni-iliac graft. 
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4.12 Optimum Timing of Endoluminal Repair 
 
Elective aneurysm repair is undertaken to prevent premature death from aortic rupture. 
As the rupture rate for aneurysms under 50mm in diameter appears to be negligible,
36
 
and the risk of rupture in patients with symptomless, slowly expanding AAAs less than 
60mm in diameter has been estimated at 0.4%, lower than the risk of elective surgery 
(1-8%), it has been suggested that such patients should not undergo surgical repair, 
but should undergo regular ultrasound follow-up.
37
 Equally, such patients should not 
undergo elective ER unless the risk of the intervention can be shown to be less than 
that of conservative treatment. 
 
It has been suggested that, as AAAs enlarge, the segments of non-dilated aorta above 
and below the aneurysm progressively shorten, the aorta lengthens and becomes 
more tortuous, and iliac artery tortuosity also increases, making ER more difficult. 
However, one study has found that aneurysms with diameters between 55-70mm 
appear no less suitable for ER than those between 45-55mm in diameter, suggesting 
that there is no anatomical advantage in operating on small aneurysms rather than 
waiting until they reach a diameter of 60mm.
32
 Given that the operative mortality 
associated with ER, and the durability of the prostheses, is unknown, there would 
appear to be no strong argument for pre-emptive ER in patients with small 
aneurysms.
20
 
 
UKSAT concluded that a policy of watchful waiting until the aneurysm diameter was 
over 55mm, or was increasing in size at a rate of over 10mm a year, was as good as 
early open repair in terms of survival. Therefore, if ER has a mortality risk similar to 
open repairs, there is no justification to perform ER until the aneurysm exceeds 55mm, 
unless ER mortality rates improve.
12
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5. METHODS  
 
5.1 Search Strategy 
 
The following strategies were used for an initial search using Medline and Embase: 
 
Medline (1995 to 1999) 
1     Aortic aneurysm, abdominal/ or 'aortic aneurysm abdominal'.mp.                                              
2      aort$.mp. [mp=title, abstract, registry number word, mesh subject  
 heading]                                             
3      aneurys$.mp. [mp=title, abstract, registry number word, mesh subject  
 heading]                                        
4      abdom$.mp. [mp=title, abstract, registry number word, mesh subject  
 heading]                                             
5      2 and 3 and 4 
6      1 or 5 
7      stent$.mp. [mp=title, abstract, registry number word, mesh subject heading]                                             
8      6 and 7 
9      Blood vessel prosthesis/ or 'blood vessel prosthesis'.mp. 
10 6 and 9 
11     8 or 10 
 
Embase (1997-1999) 
#1 AORT* 
#2  ANEURYS* 
#3  ABDOM* 
#4 #1 and #2 and #3 
#5  STENT* 
#6  BLOOD VESSEL PROSTHES* 
#7  #5 or #6 
#8  #4 and #7 
 
Current Contents/Clinical Medicine <11/17/97 - 11/09/98> 
1    aort$.mp. [mp=abstract, title, author keywords, keywords plus]                                                        
2    aneurys$.mp. [mp=abstract, title, author keywords, keywords plus]                                                        
3    stent$.mp. [mp=abstract, title, author keywords, keywords plus]                                                        
4    abdom$.mp. [mp=abstract, title, author keywords, keywords plus]                                                        
5    1 and 2 and 4 
6    blood vessel prosthes$.mp. [mp=abstract, title, author keywords, keywords plus] 
7    5 and (3 or 6) 
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5.2 Inclusion and Exclusion Criteria 
 
As these strategies combined to give a yield of 566 references, an attempt was made 
subsequently to narrow the search by searching Medline using the strategies detailed 
below to locate relevant trials, reviews and cost information. 
 
Search for trials 
1 exp aortic aneurysm, abdominal/ or 'aortic aneurysm abdominal'.mp. 
2 '##'Stent$'.mp.##'/ or Stents/ or 'stent$'.mp. 
3 Blood vessel prosthesis/ or 'blood vessel prosthesis'.mp. 
4 'RANDOMISED CONTROLLED TRIAL'.mp. 
5 Meta-analysis/ or 'meta-analysis'.mp. 
6 Controlled clinical trials/ or 'controlled clinical trial'.mp. 
7 'CLINICAL TRIAL'.mp. 
8  '##'Random$'.mp.##'/ or Random allocation/ or 'random$'.mp. 
9 (meta-anal$ or metanalys$ or meta analy$).mp. [mp=title, abstract,  
 registry number word, mesh subject heading] 
10 ((doubl$ or singl$) and blind$).mp. [mp=title, abstract, registry number  
 word, mesh subject heading] 
11     exp Clinical trials/ 
12     Cross-over studies/ 
13     1 and (2 or 3) 
14     4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 
15     13 and 14 
 
Search for systematic reviews 
1      exp aortic aneurysm, abdominal/ or 'aortic aneurysm abdominal'.mp. 
2      '##'Stent$'.mp.##'/ or Stents/ or 'stent$'.mp. 
3      Blood vessel prosthesis/ or 'blood vessel prosthesis'.mp. 
4      Meta-analysis/ or 'meta-analysis'.mp. 
5      (meta-anal$ or metatanalys$ or meta analy$).mp. [mp=title, abstract, registry number 
word, mesh subject heading] 
6     'REVIEW'.mp. 
7     exp classification/ or 'systematic'.mp. 
8     4 or 5 or 6 or 7 
9     1 and (2 or 3) 
10    8 and 9 
 
Search for cost and health economic information  
1      exp aortic aneurysm, abdominal/ or 'aortic aneurysm abdominal'.mp. 
2      '##'Stent$'.mp.##'/ or Stents/ or 'stent$'.mp. 
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3      Blood vessel prosthesis/ or 'blood vessel prosthesis'.mp. 
4      1 and (2 or 3) 
5      Costs and cost analysis 
6      4 and 5 
 
However, these strategies were not sufficiently sensitive to locate known studies of relevance. 
Therefore, the trials chosen for study were selected from those articles found using the initial 
search strategy. In addition, two key articles
38,39
 were identified from references in other articles, 
and were not located by any of the above search strategies. 
 
Other sources searched were: 
 Cochrane library; 
 CRD (DARE/NEED/HTA databases). 
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6. RESULTS  
 
6.1 Quantity and Quality of Research Available 
 
6.1.1 Evidence for the Use of Endoluminal Repair rather than Open Repair or 
Conservative Treatment 
 
Many articles have been published which describe the use of endoluminal stent-grafts 
in individual cases or in case series. However, comparative studies are few. Only one 
published randomised trial was found which compared ER with a different treatment 
modality, in this case conventional open repair.
40
 Two additional randomised trials 
compared specific aspects of ER: the relative merits of dacron and PTFE prostheses,
41
 
and the degree of inflammatory reaction following the implantation of two different 
types of sealed vascular prosthesis.
42
   
 
A further eight studies were found which compared ER with either open repair or 
conservative treatment. Two of these only compared endoluminal and open repair in 
terms of short-term biological responses rather than longer-term outcomes.
43,44
 
 
Those studies were selected for review, therefore, which compared ER with another 
form of care (either open repair or no treatment), and which made that comparison in 
terms of mortality and either morbidity or cost (for details, see Table 5). One study
40
 
reported the experiences of three separate groups of patients, only one of which was 
involved in a comparative trial. Only the results of that trial, which randomised patients 
to ER or standard open repair, are discussed here. 
 
One study specifically selected patients with aneurysms where the maximum diameter 
was 50mm.
45
  The remainder all involved patients with aneurysms where the mean 
maximum diameter was between 50 and 60mm. 
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Table 5  Studies Selected for Discussion 
 
Authors and 
Publication 
Date 
Date 
Endoluminal 
Procedures 
Undertaken 
Number of Patients Mean Patient Age  
(Years) 
Mean Aneurysm 
Size  
(mm) 
Endograft 
Configuration 
Comparison 
With: 
Length of  
Follow-up 
  Control ER Control ER Control ER    
White et al. 
1996
46
 
May 1992- 
Nov 1994 
 27  34  68.7  69.0  55  52 Tube (22) 
Bifurcated (2) 
Open repair Not stated 
Edwards et 
al. 1996
40
 
June-Sept 1994  4  4  65.3  68.3  65  65 Tube (4) Open repair 15 months (mean) 
May et al. 
1998
38
 
May 1992- 
May 1996 
 195  108  69  70  56  53 Tube (48) 
Bifurcated (35) 
Aorto-iliac/ 
Femoral (25) 
Open repair 34 months (median) 
May 1997
45
 June 1992- 
Aug 1996 
 67  43  71.4  69.6  41  44 Tube (26)  
Bifurcated (12) 
Aorto-iliac (5) 
Watchful waiting 22 months (mean) 
Brewster et 
al. 1998
47
 
Jan 1994- 
May 1997 
 28  30  73.9  75.8  55  55 Tube (8) 
Bifurcated (8) 
Aorto-uni-iliac 
(12) 
Open repair 11 months (mean) 
Hölzenbein et 
al. 1997
39
 
Feb 1995-
March 1996 
 22  22  69.5  70.1  56  53 Tube (10) 
Bifurcated (12) 
Open repair 9 months (median) 
in ER group 
Makaroun et 
al. 1998
48
 
Feb 1996- 
Feb 1998 
 69  50  71  72  59  56 Tube (15) 
Bifurcated (31) 
Aorto-iliac (4) 
Open repair by 
the same 
surgeon 
7.5 months (mean) 
Zarins et al. 
1999
49
 
 
 
18 month 
period – 
probably 1996 - 
1997 
 60  190  69  73  56  56 Medtronic 
AneuRx Stent 
Graft 
Open repair  12 months 
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6.2 Evidence for Effectiveness  
 
If a successful ER is defined as a graft placement without early or late conversion to open repair, 
graft occlusion or persistent endoleak, these studies suggest a technical success rate for ER of 
around 75-80%. When peri-operative mortality is taken into account, the overall success rate falls to 
around 70-80% (see Table 6).  
 
Peri-operative mortality, at 0-6% for ER, appears similar to (but usually lower than), that for open 
repair (0-14%). Lower too is the rate of systemic/remote complications (i.e. medical complications, 
such as, renal insufficiency, cardiac failure and stroke, which are related to the patient’s general 
medical condition).
50
 These stand at 0-29%, compared with 0-64% for open repair (see Table 6). 
The most recent (third) RETA report is suggesting similar mortality rates for ER when compared to 
the mortality rates of open repairs in the same units.  
 
ER appears to carry a higher rate of local/vascular complications (i.e. complications directly related 
to the method of AAA repair, such as, damage to arteries, graft stenosis and groin wound 
complications)
50
 than does open surgery (19-57% compared with 0-15% - see Table 6). Moreover, 
these rates will rise if immediate conversion to open repair is included as such a complication rather 
than a planned back-up manoeuvre.
46
 However, if conversion to open repair is excluded, the 
local/vascular complications associated with ER tend to be less severe than the systemic/remote 
complications which predominate in open repair.
47 
 
6.3 Quality of the Research 
 
The quality of the studies on which these conclusions are based is not good. The weaknesses 
included both weaknesses of design and of reporting. Moreover, in general, uncontrolled, non-
randomised observational studies are associated with an over/under-estimation of treatment effects 
which may be suggested through fully randomised controlled trials.
51
 When using observational 
study evidence, conclusions can be drawn using statistical comparisons, such as meta-analysis; 
however, such methods carry dangers in terms of confounding factors and study bias.
52 
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Table 6a  Outcome Measures: Mortality, Complications and Success Rates   
 
Study White et al. 
1996
46
 
Edwards et al. 
1996
40
 
May et al.  
1998
38
 
May et al.  
1997
45
 
Brewster et al. 
1998
47
 
 Control ER Control ER Control ER Control ER Control ER 
Immediate/ very 
early 
conversion to 
open repair 
Not 
applicable 
18% 
(6/34) 
Not 
applicable 
0% 
(0/4) 
Not 
applicable 
12% 
(13/10
8) 
17% 
(11/65)  
4 open 
and 7 ER 
because 
of 
aneurysm 
growth 
14% 
(6/43) 
Not 
applicable 
7 
(2/30) 
Peri-operative 
mortality 
3.7% 
(1/27) 
0% 
(0/34) 
0% 
(0/4) 
0% 
(0/4) 
6% 
(11/195) 
6% 
(6/108) 
1.5% 
(1/65) 
(1 death 
from 
aneurysm 
rupture) 
5% 
(2/43) 
0% 
(0/28) 
0% 
(0/28) 
Local/vascular 
complications 
15% 
(4/27) 
25% 
(7/28) 
0% 
(0/4) 
50% 
(2/4) 
9% 
(17/195) 
26% 
(28/10
8) 
Not 
applicable 
19% 
(8/43) 
7% 
(2/28) 
57% 
(16/28) 
Systemic/ 
remote 
complications 
37% 
(10/27) 
29% 
(8/28) 
0% 
(0/4) 
0% 
(0/4) 
20% 
(38/195) 
18% 
(18/10
8) 
Not 
applicable 
23% 
(10/43) 
64% 
(18/28) 
14% 
(4/28) 
Late 
complications  
Not stated Not 
stated 
0% 
(0/4) 
25% 
(1/4) 
0.5% 
(1/195) 
6% 
(6/108) 
Not 
applicable 
7% 
(3/43) 
Not 
stated 
18% 
(5/28) 
Late 
conversion to 
open repair 
Not 
applicable 
7% 
(2/28) 
Not 
applicable 
25% 
(1/4) 
Not 
applicable 
6% 
(7/108) 
Not 
applicable 
0% 
(0/43) 
Not 
applicable 
7% 
(2/28) 
Early + late 
conversion 
Not 
applicable 
23% 
(8/34) 
Not 
applicable 
25% 
(1/4) 
Not 
applicable 
19% 
(20/10
8) 
Not 
applicable 
14% 
(6/43) 
Not 
applicable 
13% 
(4/30) 
Patients free of 
complications 
55% 
(15/27) 
57% 
(16/28) 
100% 
(4/4) 
50% 
(2/4) 
Not 
stated 
Not 
stated 
Not 
applicable 
Not 
stated 
 
54% 
(15/28) 
50% 
(14/28) 
Technical 
success rate* 
Not stated 76% 
(26/34) 
100% 
(4/4) 
75% 
(3/4) 
99% 
(194/195) 
77% 
(83/10
8) 
Not 
applicable 
79% 
(34/43) 
Not 
stated 
77% 
(23/30) 
Success rate** Not stated 76% 
(26/34) 
100% 
(4/4) 
75% 
(3/4) 
94% 
(183/195) 
71% 
(77/10
8) 
Not 
applicable 
74% 
(32/43) 
Not 
stated 
77% 
(23/30) 
*  i.e. graft successfully placed using intended technique (in the case of ER, without late conversion to open repair or persistent endoleak) 
**  i.e. graft successfully placed using intended technique without death within 30 days of implantation and, in the case of ER, without late conversion to open repair, graft 
occlusion  or persistent endoleak 
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Table 6b  Outcome Measures: Mortality, Complications and Success Rates (cont'd) 
 
 
 
Hölzenbein et al. 
1997
39
 
Makaroun et al.  
1998
48
 
Zarins et al. 
1999
49
 
 Control ER Control ER Control ER 
Immediate/ 
very early 
conversion to 
open repair 
Not 
applicable 
0% 
(0/22) 
Not 
applicable 
6% 
(3/50) 
Not 
applicable 
0% 
(0/190) 
Peri-operative 
mortality 
14% 
(3/22) 
0% 
(0/22) 
0% 
(0/69) 
2% 
(1/50) 
0% 
(0/60) 
3% 
(5/190) 
Local/vascular 
complications 
Not stated Not stated Not stated 40% 
(20/50) 
12% 
(7/60) 
9% 
(16/190) 
Systemic/ 
remote 
complications 
Not stated Not stated Not stated 4% 
(2/50) 
12% 
(7/60) 
3% 
(6/190) 
Late 
complications  
Not stated Not stated Not stated 14% 
(7/50) 
Not stated Not stated 
Late 
conversion to 
open repair 
Not 
applicable 
Not stated Not stated 0% 
(0/50) 
Not 
applicable 
0% 
(0/190) 
Early + late 
conversion 
Not 
applicable 
Not known Not 
applicable 
6% 
(3/50) 
Not 
applicable 
0% 
(0/190) 
Patients free 
of 
complications 
Not stated Not stated Not stated Not stated Not stated Not stated 
Technical 
success rate* 
Not stated Not stated Not stated 80% 
(40/50) 
98% 
(59/60) 
77% 
(146/190) 
Success rate** Not stated Not stated Not stated 78% 
(39/50) 
77% 
(46/60) 
78% 
(146/190) 
 
*  i.e. graft successfully placed using intended technique (in the case of ER, without late conversion to open repair or persistent endoleak) 
**  i.e. graft successfully placed using intended technique without death within 30 days of implantation and, in the case of ER, without late conversion to open repair, graft 
occlusion  or persistent endoleak 
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Some of the weaknesses of design were inevitable, given the desire to share 
information about the new procedure sooner rather than later. These appear to have 
affected all the studies, and include: 
 
 comparing a new technique involving a range of early prototype devices with an 
established surgical technique;
46,53
 
 
 inadequate length of follow-up. 
 
Of these, the latter is perhaps the more problematic since it may lead to unrealistic 
expectations for the procedure. In none of the studies was the length of follow-up 
sufficient to allow all late complications to emerge and the long-term success of the 
procedure to be estimated. The study, of patients who had undergone ER with the 
longest duration, had a median follow-up of 29 months.
54
  This is particularly 
problematic, since it is not yet known whether the dilatation of the proximal aortic neck 
at the site of proximal device fixation (which accompanies the reduction in diameter of 
the aneurysmal sac brought about by successful AAA exclusion) is progressive and 
whether, if so, it results in device migration with subsequent endoleakage.
24
  Moreover, 
the durability of the devices, and the most successful means of attachment given the 
possibility of changes in arterial size over time, are, as yet, unknown.
24,40
 
 
In addition to the above weaknesses of design, two teams
48,54,55
 acknowledge a 
problem which is likely to have affected all, namely the relative inexperience of the 
clinicians involved in endoluminal techniques. The potential impact of this is indicated 
by one team which notes that both of the peri-operative deaths and four out of six 
conversions to open repair occurred early in the course of their study, and attributes 
this to the learning curve for the new technique;
55
 the same team found that the 
primary conversion rate fell from 20% to 8% as they gained experience.
54
 
 
Another weakness, which appears to affect all the studies which compare endoluminal 
with open repair, was not inevitable. This is the more intensive follow-up of the 
endoluminal group, which made it more likely that any failures or complications would 
be discovered in these patients than in those who underwent open surgery. Indeed, 
two studies compared prospectively recorded data for ER with retrospectively analysed 
data for open repair, and their authors note that this may have led them to 
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underestimate the incidence of complications for open repair.
46,54
  Blinding of outcome 
assessors to treatment allocation, if feasible, does not appear to have been attempted 
in any of the studies. 
 
It may be seen, then, that one of the biases introduced by the various weaknesses of 
study design (inadequate length of follow-up) favours, and others (newness of the 
technique, relative inexperience of the clinicians, more intensive follow-up of the 
intervention group) disadvantage, ER. 
 
Many of the studies also include weaknesses of reporting, which introduce bias which 
would appear to favour open repair. Four of the six studies, which compare ER with 
open repair, do not provide as much information about the outcomes of the latter as 
the former, often failing to provide comparable information on complication rates and 
appearing to assume that open repair invariably results in successful graft placement. 
Other studies suggest that this is not necessarily so. Although the success rate of 
conventional surgery is high, in excess of 93%,
24
 it may have a late complication rate 
as high as 2%.
18
 Four out of six studies, however, fail to comment on the late 
complication rate in this group (see Table 6). 
 
One study did not use intention to treat analysis,
47
 whilst another, which states that it 
did, does not report the data in this format.
46
 
 
In addition, one of the studies
48
 presents information relating to the group of patients 
undergoing ER in such a manner that some uncertainty attends the data summarised 
in Table 6 on complications in patients from this study undergoing ER. 
 
 
6.4 Generalisability of Trial Results 
 
The generalisability of the trial results is uncertain because of the highly specialised 
nature of the procedure involved, which argues for its concentration in a limited 
number of centres. The training required to perform ER is considerably different from, 
and more intensive than, that for conventional surgical repair. Following training, 
endoluminal procedures must be carried out frequently and regularly to maintain 
individual and team proficiency.
30
  However, as two teams comment on their initial 
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relative inexperience in endoluminal techniques,
48,55
 it may be that comparable results 
could be achieved elsewhere on comparable patient groups. 
 
A more serious problem in terms of generalisability is the fact that ER is generally 
considered an attractive option for patients who are at high risk for surgery. However, 
the majority of the above studies took as their subjects patients who were suitable for 
open surgery. In only two studies was suitability for surgery not a condition of 
enrolment. One of these
55
 compared ER with conservative treatment. This left only 
one
54
 which compared ER in a population 44% of whom were unsuitable for open 
surgery with open repair within a population which was suitable for surgery. This is also 
the study which reports the lowest overall success rate (although, given the small 
numbers treated in some of the other studies, this may not be statistically significant). 
Therefore, it is possible that less favourable results will be obtained if ER is used to 
treat increasing numbers of patients at high risk for open repair. 
 
Moreover, the endoluminal devices currently available are likely to be better than those 
used in the studies discussed above. One team states that four out of six conversions 
to open repair occurred with devices which are now superseded.
53
  In addition, more 
recent devices may be introduced using smaller, more flexible access sheaths, and 
this is likely to reduce the incidence of vascular complications.
53
 
 
 
6.5 Outcomes 
 
6.5.1 Benefits of Endoluminal Repair 
 
Potential benefits which have been claimed for ER in comparison with open repair 
include the reduction of post-operative morbidity and pain, less compromise of 
gastrointestinal function, earlier return to normal diet, improved respiratory function, 
earlier mobilisation and earlier return to normal activity.
46
  Only one of the studies 
reviewed above
47
 includes in its list of outcomes the time taken from hospital discharge 
to return to a feeling of pre-operative well-being. Some of the other studies address 
this benefit indirectly in terms of factors such as mean operative time, blood loss, 
length of ITU stay, and length of hospital stay. This information is summarised in Table 
7. 
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These benefits assume that ER is used in patients who would otherwise have 
undergone open repair. However, it could be argued that, when complication rates are 
taken into account, the benefits of ER are relatively slight for patients who are suitable 
for open repair, and that the real benefit of ER is that it enables patients who would not 
have been suitable for surgery to undergo aneurysm repair.  
 
6.5.2 Disbenefits 
 
Of those who are suitable, a significant proportion will require conversion to open 
repair either immediately or at a later date; the studies reviewed here suggest that this 
proportion may be as high as 25% (see Table 6). Converting an endoluminal 
procedure to open repair is often technically more complicated than a standard open 
repair and, therefore, may result in a high morbidity and mortality rate - one study 
indicated a mortality rate of 17%. While the risk of requiring conversion is equal in all 
patients, whether or not they were originally considered suitable for open repair, 
perhaps unsurprisingly the risk of death as a result of conversion for patients originally 
rejected for open repair because of comorbidities appears to be as high as 43%.
56
 
 
A number of complications are associated with ER, one of the most serious of which is 
renal impairment. However, only that complication which is most directly attributable to 
ER, and which is perhaps the most common complication of such repair, endoleakage, 
is discussed here. Persistent endoleaks have been shown to be correlated with AAA 
expansion and possibly rupture. The reported occurrence of early endoleak ranges 
from 10% to 44% and, although as many as 50% of these may seal spontaneously 
weeks or months after endograft implantation, some of these apparently self-correcting 
leaks may recur later.
47
 Because of the relatively short follow-up period in the reported 
studies, it is not known how many patients will ultimately require further endoluminal 
procedures or conversion to open repair as a result of recurring endoleaks. 
 
It has also been suggested that, if conventional open repair is required following ER, 
this may be more difficult or complex because of that earlier repair.
47
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Table 7a  Outcome Measures: Operative Time, Blood Loss, Length of ITU and Hospital Stay 
 
Study White et al. 1996
46
 Edwards et al. 
1996
40
 
May et al.  
1998
54
 
May et al.  
1997
55
 
Brewster et al. 
1998
47
 
 Control ER Control ER Control ER Control  ER Control ER 
Mean operative 
time (hours) 
2.58 3.1 2.4 2.3 Not 
stated 
Not 
stated 
Not 
applicable 
Not 
stated 
3.52 3.25 
Mean blood loss 
(ml) 
1,422 873 Not 
stated 
Not 
stated 
1,271 556 Not 
applicable 
Not 
stated 
1287 498 
Mean units of 
blood transfused 
Not 
stated 
Not 
stated 
Not 
stated 
Not 
stated 
Not 
stated 
Not 
stated 
Not 
applicable 
Not 
stated 
Not 
stated 
Not 
stated 
Mean length of 
ITU stay (days) 
1.8 0.7 Not 
stated 
Not 
stated 
2.1 0.8 Not 
applicable 
Not 
stated 
1.75 0.1 
Mean length of 
hospital stay 
(days) 
12.4 11.1 5.3 1.8 11.7 10.5 Not 
applicable 
Not 
stated 
10.3 3.9 
Mean time from 
hospital 
discharge to 
return of a feeling 
of pre-operative 
well-being (days) 
Not 
stated 
Not 
stated 
Not 
stated 
Not 
stated 
Not 
stated 
Not 
stated 
Not 
applicable 
Not 
stated 
47 11 
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Table 7b Outcome Measures: Operative Time, Blood Loss, Length of ITU and Hospital Stay (cont'd) 
 
Study Hölzenbein et al. 
1997
39
 
Makaroun et al. 
1998
48
 
Zarins et al. 
1999
49
 
 Control  ER Control ER Control ER 
Mean operative 
time (hours) 
3.82 
(median 
time) 
3.47 
(median 
time) 
Not 
stated 
3.0* 3.6 3.1 
Mean blood loss 
(ml) 
Not 
stated 
Not 
stated 
Not 
stated 
212** 1596 641 
Mean units of 
blood transfused 
2.73 0.55 Not 
stated 
Not 
stated 
1.6 0.3 
Mean length of 
ITU stay (days) 
2.29 0.95 Not 
stated 
Not 
stated 
2.5 0.9 
Mean length of 
hospital stay 
(days) 
22.8*** 14.9*** 5.9 2.5**** 9.4 3.4 
Mean time from 
hospital 
discharge to 
return of a feeling 
of pre-operative 
well-being (days) 
Not 
stated 
Not 
stated 
Not 
stated 
Not 
stated 
Not 
stated 
Not 
stated 
 
*     Mean time for the successful procedures; mean time for the 3 which needed immediate conversion to open repair was 6.1 
**    For the successful procedures; 2,866 for the 3 which needed immediate conversion to open repair 
***   Includes admissions for pre-surgical testing averaging 3.0 days in the control group and 7.2 days in the ER group 
****  For the successful procedures; 3.2 including those which needed immediate conversion to open repair. 
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6.6 Conclusions about Outcomes from Endovascular Abdominal Aortic Aneurysm 
Repair 
 
A number of comparative, but non-randomised, studies were identified which showed that 
endoluminal AAA repair has a lower peri-operative mortality rate than open repair; a further 
study compared ER with watchful waiting. Four studies suggested that ER had a lower rate 
of systemic/remote complications than open repair, but four showed that it had a higher rate 
of local/vascular complications. Peri-operative mortality was similar for each type of 
intervention, but longer-term outcome comparisons are still largely unknown. The overall 
success rate of ER (i.e. successful placement, no endoleak and without mortality by 30 
days) was between 70-80%; between 6-25% of patients had to undergo immediate or late 
conversion to open repair. 
 
6.7 Economic Analysis  
 
The literature search found no published papers reporting formal cost-effectiveness or cost-
benefit analyses comparing ER with either open repair or more conservative medical 
treatments. Ideally, the authors would like to be able to calculate costs per quality adjusted 
life year (QALY) ratios for these alternative treatment regimens. The choice of alternative 
treatments depends upon the patient groups being analysed and, specifically, whether or 
not patients are fit or suitable for open surgery. The lack of published evidence about the 
longer term benefits of ER and the constantly changing stent technology, makes any 
economic evaluation of ER particularly difficult at this time. 
 
 
6.7.1 Estimation of Net Benefits  
 
The benefits of ER of AAA depend upon the patient groups being treated. Four patient 
groups can be defined: - 
 Patients unsuitable for ER; 
 Patients fit for either open repair or ER; 
 Patients unfit (or unsuitable) for open repair; 
 Patients with small aneurysms. 
 
Patients unsuitable for ER (e.g. for anatomical reasons) are not affected by the advent of 
endovascular treatment and, therefore, are not considered further here. 
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Key benefits to the group fit for either type of surgical intervention include the short-term 
advantages of a less invasive procedure. The long-run benefits in terms of life years gained 
and QALYs are uncertain and will depend on factors such as the peri-operative and longer-
term complication rates (e.g. endoleaks, subsequent re-operation, and ruptures) and 
mortality rates associated with the two procedures. The benefits to fit patients are the 
subject of the Endovascular Aneurysm Repair (EVAR)1 clinical trial.  
 
The benefits to unfit patients are clearer in that an operative procedure is now available to a 
group previously unfit for surgical intervention. Consequently, there is clear potential for 
extending life for those patients who would otherwise die early from a ruptured aneurysm. 
The net benefit in terms of life years gained will depend on the trade-off between the short- 
and longer-term risk of endoluminal surgery, versus the risk of death from rupture, when 
there is no elective operative intervention. The latter will in turn be dependent on aneurysm 
expansion rates. Other things being equal, the relative life expectancy for the unfit group of 
patients will be lower than for the general population. As such, the life years gained from 
endoluminal intervention can be expected to be relatively low. The benefits to unfit patients 
are the subject of the EVAR2 clinical trial.  
 
The relative benefits of endovascular surgery for patients fit, but unsuitable, for open repair 
(e.g. because of a hostile abdomen) will be similar to those in the unfit group except that in 
general, this group of patients will have a longer life expectancy than the unfit patients. 
Consequently, there is potential for greater life years gained from the endoluminal 
procedure for this patient group. This group of patients is not explicitly part of the EVAR 
trials. 
 
The benefits for the small aneurysm group are particularly uncertain. The UKSAT concluded 
that elective open repair was an unnecessary intervention for aneurysms smaller than 
55mm in diameter. It needs to be established whether (or by how much) reductions in the 
short- and long-term risks from endovascular surgery can make the intervention a cost-
effective alternative to conservative treatment for the small aneurysm patient group.
12
  
 
Consequently, the benefits of ER in terms of additional life years gained (quality adjusted or 
not) are very uncertain at this point in the development of the technology. The benefits to 
patients will also vary by patient group. A modelling exercise and/or the results of the EVAR 
trials should help to inform the current uncertainties around the benefits of this relatively new 
intervention. 
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6.7.2 Estimation of Net Cost 
 
NHS costs of the new endoluminal procedure   
 
There are substantial direct costs associated with ER compared with open repair, namely:   
 
 Additional screening tests are required to determine whether the patient is anatomically 
suitable for ER;
39
 
 
 The stented endografts used are all more expensive than standard vascular grafts, and 
additional endovascular instruments (guide wires, balloon catheters and special task 
catheters) are also required;
39
 
 
 To allow for immediate conversion to open repair, if necessary, ER must be undertaken 
in an operating theatre, which must also be equipped with the state-of-the-art imaging 
systems required for ER. This may require major investment.
18,39
 The need for 
conversion will be dependent on patient selection criteria. 
 
 The cost of follow-up is greater than for standard repair because of the need for 
additional radiological examinations.
39
 
 
The longer-term costs for ER are uncertain because of the uncertainties surrounding the 
longer-term complication rates for the procedure, particularly the endoleak rates and the 
likely need for further surgical intervention for endoleak repair. Moreover, the constantly 
improving stent technology will influence both the longer- and shorter-term success of the 
intervention. These technological changes and the lack of longer-term follow-up evidence 
for endoleak repair make it particularly difficult to assess the true marginal opportunity cost 
for this procedure.  
 
In addition, as ER can also be used to treat patients at high risk from open repair, the 
number of patients with AAA who undergo aneurysm repair may rise and, therefore, the 
overall costs of the service will increase. On balance, it seems reasonable to expect that 
treatment costs for such patients will be higher than those for fitter patients, given that 
complication and open conversion rates are likely to be higher for unfit patients. Balancing 
this, however, is the potential reduction in ruptured aneurysms - the costs of emergency 
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repair were estimated at £10,500 by the UKSAT team.
12
  This figure is more than double 
their estimate of the costs for elective repair.  
 
NHS Savings from the New Endoluminal Procedure  
 
ER can lead to cost savings associated with reductions in ITU and hospital stays compared 
with open repair.
39
 Those studies which provided the relevant information stated that ITU 
stay was more than halved in patients undergoing endoluminal compared with open repair 
(see Table 7). The study which reported the longest ITU stay for patients undergoing ER
39
 
noted that this was due to the ethics committee’s requirement that these patients should 
undergo special surveillance in an ITU for at least 12 hours, and that none of them required 
ITU admission for medical reasons; in the same study, the group undergoing open surgery 
was not routinely admitted to ITU.
39
 
 
In addition to the reduction in ITU stay, all of the studies reported a reduction in hospital stay 
in those patients who underwent ER (see Table 7). However, in some cases the reduction 
was relatively small (around 10%). In one such case, the authors stated that length of 
hospital stay for patients undergoing ER was influenced by the fact that they were often 
kept in hospital for extra days to observe for known and unknown complications, because 
the procedure was so new, and to allow for complete follow-up imaging, rather than strictly 
for medical indications.
46
  In another instance, although the mean length of hospital stay for 
ER was substantially shorter than that for open repair, it was, nonetheless, longer than in 
any of the other studies, and was protracted because the local, Austrian, reimbursement 
policy encouraged the performance of the entire pre-operative evaluation on an in-patient 
basis. However, the post-operative length of stay (averaging 13.3 days for open surgery and 
5.6 days for ER) was said to be comparable with that reported in the literature.39 Moreover, 
this study noted that all patients who had undergone ER were discharged home, but that 
some of those who had had open repair were transferred to other hospitals or secondary 
care facilities.
39
 It seems likely, therefore, that, as the technique becomes established, the 
average length of stay of patients undergoing successful endoluminal graft implantation may 
well be less than half that of similar patients undergoing open repair. However, as noted 
above, two of the studies exclude from their published analysis those patients who had to 
undergo immediate conversion to open repair, and the difference between endoluminal and 
open repair in terms of average lengths of stay, based on an intention to treat analysis, is 
likely to be less favourable to ER. 
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Net Costs 
The costs of the ER procedure itself have been estimated to be almost three times higher 
than the procedural costs for open surgery - 10,700 ECU (£8,560 using ECU = £0.8 
exchange rate) versus 4,032 ECU (£3,225). These figures are in 1996 currency and are for 
patients considered fit for both types of procedure. The costs of the radiological testing were 
estimated to be five times higher for endoluminal compared with open procedures.
39
 
 
Hölzenbein has estimated the total cost of the whole intervention to be 25,374ECU 
(£20,300) for open repair and 22,269 ECU (£17,815) for ER.
39
 This is a 14% difference in 
favour of ER. The reduced costs are a result of a faster patient recovery associated with a 
shorter length of hospital stay. The Hölzenbein analysis is unsatisfactory in a number of 
ways, however. The sample size of 44 is small and atypical in that no patients required 
conversion from endovascular to open repair. The latter biases the results in favour of ER. 
Indeed, another study found that, when the cost of failed, as well as successful, ER was 
taken into account, the cost of the device and interventional supplies used during the 
procedure almost exactly offset the cost savings derived from the reduction in hospital 
stay.
48
 On the other hand, as discussed above, hospital and ITU lengths of stay were longer 
than necessary. Also, tertiary sector care costs were excluded from the analysis. Both these 
effects bias the results against ER.  
 
The UKSAT
12
 has enabled a comparison of the NHS costs and benefits of surgical versus a 
more conservative regimen involving radiological assessment.
12
 The analysis indicates that 
for aneurysms of 40-55mm diameter the conservative ‘watch and wait’ regimen is cheaper 
than early surgical interventions over a wide range of assumptions (£5,000 versus £4,000 at 
1996/97 prices using a 6% discounting rate). The cost of ER was estimated at £6,800, 
though this figure is calculated using only a small sub-group of the whole trial population 
(12/1,090). In contrast to the Hölzenbein results, this UK study indicates a higher cost for 
endovascular compared with open repair, although the costs of both procedures are 
considerably less than those estimated in Austria. Having said this, the UK estimate for the 
endovascular costs did use the unrepresentative ITU length of stay data from the Austrian 
study, which will have increased the estimated costs for this procedure. Jepson
57
 has 
estimated the cost of elective AAA repair at £4,600 (1993 prices) in Scotland. Allowing for 
inflation, this is a similar figure to that reported by the UKSAT.  
 
Using a bottom-up costing approach with information provided by Sheffield’s Northern 
General Hospital, some costs have been estimated for the repair of AAA. Making 
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assumptions about the device costs, theatre time, and post-operative (High Dependency 
Unit (HDU)/ITU and ward stays and per diem costs), the costs of the ER are estimated to be 
circa £7,500 for a fit patient and £8,300 for an unfit patient.  The costs for an elective open 
repair are similarly estimated to be circa £6,300 for a fit patient.  Most of the EVAR cost 
relates to the device and consumables (£5,000), whereas most of the cost of the elective 
open repair relates to the ITU and ward stays (£6,200).  The costs of an emergency open 
repair of a ruptured aneurysm have been estimated at £6,500 for those patients not 
surviving the operation and £13,000 for the small percentage of survivors. 
 
Thus, there are a number of estimated costs and savings for endovascular and open 
elective and emergency repair of AAAs. These derive from a variety of published and 
unpublished sources, from different healthcare contexts, and for different patient types. 
Therefore, their use and comparison should be treated with caution. The published 
estimates for the costs of an endovascular procedure are particularly uncertain, ranging 
from 14% less to 20% more than open repair. The endovascular procedure costs are 
particularly difficult to estimate given that the stent technology is still in a developmental 
stage, so that the procedure costs and the operative and post-operative complication rates 
are constantly changing. The sensitivity of the costings to realistic ITU and overall hospital 
bed utilisation makes it hard to give an overview at this stage. Perhaps the best one can say 
is that the ER and elective open repair procedures cost similar amounts.  Ignoring the 
benefit implications from life years gained or lost, emergency open repair of ruptured AAA 
can cost considerably more than the elective procedures. 
 
6.7.3 Estimation of Cost-effectiveness and/or Cost Utility  
 
There are no published papers reporting a formal economic analysis of endovascular AAA 
repair comparing it to either open repair or conservative management. Three patient groups 
have been identified for whom the cost-effectiveness of ER needs assessing. The cost-
effectiveness will differ by patient group, as will the available alternative treatments.  
 
 Patients unfit (or unsuitable) for open repair who could undergo the less invasive 
endovascular procedure rather than waiting for an emergency repair of a ruptured 
aneurysm, which carries a high risk of pre- or peri-operative death and higher costs.  
Key variables are likely to be the rupture rate for the untreated group and the mortality 
rates for this relatively unfit group. 
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 Those patients fit for either elective open repair or ER. For such patients the authors 
were interested in modelling the comparative costs and benefits (long-term survival for 
example) of the two procedures. 
 
 Those patients with small aneurysms. Evidence from the small aneurysm trial indicates 
that early open surgery is not as cost-effective as conservative management using 
radiological watchful waiting. Assuming that this finding is accepted as good practice, it 
now needs to be established how the cost-effectiveness of the endoluminal procedure 
compares with that of conservative management. 
 
Ideally, the authors are interested in measuring the marginal costs per QALY gained.  Due 
to the lack of published evidence and the constantly improving technology surrounding 
endovascular stenting, there are significant areas of uncertainty and ignorance particularly 
about long-term success (e.g. in terms of endoleakage) and survival rates for the 
endoluminal procedure. As such, the authors are reluctant to comment here on the relative 
cost-effectiveness of ER of AAA. A decision analysis modelling approach could help to 
identify threshold values for key variables identifying the points at which endovascular 
surgery would become a cost-effective option compared with a named alternative for the 
various patient groups identified above. Two of the authors of this paper (Thomas and 
Calvert) are currently undertaking cost-effectiveness analyses of ER of AAA using decision 
analysis and Markov modelling. The results of this work are expected to be submitted for 
publication in 2000 and will consider the above patient groups. Sensitivity analysis during 
the modelling process should enable the estimation of relevant threshold values for key 
variables, and could help identify which variables the EVAR trials should focus their efforts, 
in terms of obtaining more accurate estimates. In the light of the conclusions and 
recommendations of this Guidance Note, the scope of this modelling work was considered 
to be beyond the remit of this report. Early results from this modelling work analysing the 
cost effectiveness of ER for the unfit and unsuitable patient groups have been made 
available during the final drafting of this paper. The results indicate that ER is likely to have  
favourable cost-effectiveness in terms of life years gained for both the unfit and particularly 
the ‘fit but unsuitable’ for open repair groups of patients.  Results are not currently available 
for the fit patient groups. 
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7. IMPLICATIONS FOR OTHER PARTIES  
 
This report has raised a number of important issues, which have implications for other 
parties, both in respect of this specific procedure and clinical area, and more widely in the 
introduction of new health technologies. These issues are listed below: 
 
 With the advent of Clinical Governance, are there lessons to be learned from the 
introduction of stents, the Safety and Efficacy Register of New Interventional Procedures 
(SERNIP), (see Appendix A), and the Registry for Endovascular Treatment of 
Aneurysms (RETA)? 
 
 What mechanisms are in place in Trusts to oversee the introduction of new procedures 
before they come to the notice of SERNIP (cf. ethics committees for research 
proposals)? Is there any guidance on obtaining patient consent? 
 
 Registration with RETA is voluntary, and has been incomplete for a number of reasons, 
not least resources for the registration process. 
 
 RETA has had difficulty in obtaining the co-operation of device manufacturers (except 
for two) in establishing a parallel register of devices supplied as a means of validating 
RETA. 
 
 There appears to be a two tier regulatory system, with device manufacturers being 
subject to far less stringent regulations than drug manufacturers. 
 
 There is a well recognised path of drug development: laboratory, animal and three 
phases of human studies. Could a parallel path be established for devices? 
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8. EQUITY ISSUES 
 
Circulatory disease has been selected as one of the four target areas in the recent White 
Paper 'Saving Lives: Our Healthier Nation'.
58
 This area has been included because, 
amongst other reasons, there are substantial inequalities in health in this disease area. 
Implementation of improved care to prevent adverse effects from aortic aneurysms must 
ensure that relevant treatment reaches all population groups in an equitable manner, as 
there is evidence that other interventions in respect of circulatory disease have not always 
reached those with greatest need in more deprived areas.
59
 
 
 
9. OTHER UNQUANTIFIABLE FACTORS  
 
Perhaps the main opportunities for prevention are in the reduction of cigarette smoking and 
good control of hypertension – it is unclear at present how much impact past, current and 
future initiatives in this area will have on the epidemiology of AAAs.  
 
 
10. OPTIONS FOR PURCHASERS/COMMISSIONERS  
 
Three main options present themselves for purchasers/commissioners of health services: 
 
1.  Do not change current contracting arrangements. 
 
2.  Purchase endovascular AAA repair only in the context of the current trials (notably 
EVAR1 and 2). 
 
3.  Purchase for patients deemed clinically suitable, but insist that centres undertaking 
these procedures provide clear audit results of their outcome and participate in the 
RETA database. 
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11. CONCLUSIONS 
 
11.1 Main Results 
 
A number of comparative, but non-randomised, studies were identified (taken together, a 
total of nearly 1,000 patients, split between either endoluminal or open repair, were 
included). These showed that endoluminal AAA repair has a lower peri-operative mortality 
rate than open repair; a further study compared ER with 'watchful waiting'. Four studies 
suggested that ER had a lower rate of systemic/remote complications than open repair, but 
four showed that it had a higher rate of local/vascular complications. Peri-operative mortality 
was similar for each type of intervention, but longer-term outcome comparisons are still 
largely unknown. The overall success rate of ER (i.e. successful placement, no endoleak 
and without mortality by 30 days) was between 70-80%; between 6-25% of patients had to 
undergo immediate or late conversion to open repair. 
 
It is possible that, after the initial outlay involved in equipping theatres to undertake ER, the 
procedure may be no more expensive than open repair. However, if the procedure is used 
to increase the number of patients undergoing aneurysm repair, the overall costs of the 
service will rise, perhaps substantially. 
 
11.2 Assumptions, Limitations and Uncertainties 
 
The design of the studies was variable. Some had specific flaws as discussed above. The 
lack of long-term follow-up is particularly worrying. The generalisability of the results is 
questionable given the limited inclusion criteria, with most of the studies only recruiting 
patients suitable for open surgery. 
 
11.3 Need for Further Research 
 
Further research is needed to assess the long-term effects of endoluminal aneurysm repair. 
While it may appear that there is little to lose in undertaking such repair in patients who are 
not suitable for open repair, it has been suggested that prospective randomised studies with 
follow-up for at least five years will be required to determine the potential role of endoluminal 
grafting of AAA in the patient who is fit for conventional open repair.
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As discussed earlier, a UK randomised controlled trial (with two components EVAR1 and 
EVAR2) is planned to start in 1999. It has been delayed many times and there are a number 
of problems still being raised. In particular, there is a view that the intervention is not yet 
'mature' with practitioners still on a learning curve and devices still being modified. The trial 
design requires that open surgery controls must be operated on and followed up in the 
same centres as stent cases. Funding arrangements are unclear as workload shifts from 
district general hospitals to specialist centres and some of these may not have sufficient 
capacity especially in ITUs. 
 
Two issues must be addressed in addition to the simple comparison with open surgery. 
Firstly, what are the benefits of stents in treating patients unsuitable for open surgery, who 
contribute disproportionately to the aorto-uni-iliac + crossover group with its necessity for 
open procedure and higher mortality (RETA)? 
 
Secondly, if death rates for stents are no better than those in open procedures (RETA), and 
given the results of the Small Aneurysms Trial,
12
 will there be any justification for treating 
smaller aneurysms (<55mm) or, indeed, ethical justification for a trial to find out? Figure 1 
illustrates the options for the management of aortic aneurysms expressed as a trial protocol. 
The planned EVAR trial does not address the issue of stenting small aneurysms ( 55mm), 
yet whether stenting small aneurysms is, or is not, effective and cost-effective is crucial to 
any debate on the introduction of aneurysm screening. 
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Figure 1 Management Options for Asymptomatic Abdominal Aortic Aneurysms: 
Research Protocol 
 
 
 
SMALL ANEURYSMS
 55mm and increasing
in size by10mm
pa
LARGER ANEURYSMS
> 55mm or increasing in
size by >10mm
pa
Ultrasonic monitoring at 6
or 3 monthly intervals
'watchful waiting'
Suitable for
ER NO
YES
Endoluminal (stent) repair
Suitable for open repair?
NO
Open repair*
Suitable for
ER?
Randomise to Stent
or no treatment
(EVAR II)
Randomise to stent or
watchful waiting (A)
YES
Randomise to Stent
or open repair
(EVAR I)
YES
Stent** No treatment
Notes:
(A) there is no research planned for this area, but the outcome of such a trial would be
crucial to any decision concerning the introduction of screening for aortic aneurysms, as
the introduction of a screening programme would be predicated on the existence of an
effective and safe intervention.
* These patients are to be operated on at the same centres as the stents arm.  This will
constitute a shift in activity from DGHs to research centres.  Who is to fund this arm?  Will
DGH surgeons choose not to recruit to the trial to avoid losing open procedures to the
trial (thus threatening the trial)?
** Are these to be funded at full cost by the trial or at marginal cost over open repair? If
the latter, the financial problems caused by the shift from DGH to centre as above will
apply to this arm as well, though more problematic for non-(trial)-host HAs.
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EXPIRY DATE 
 
The conclusions based on this guidance note will need to be revisited when the UK 
randomised controlled trials mentioned above report. This is expected to be in five years' 
time. 
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APPENDIX A Safety and Efficacy Registry of New Interventional Procedures 
of the Academy of Medical Royal Colleges (SERNIP) 
 
This is the first Trent DEC report covering a topic which has also been reviewed by the 
Safety and Efficacy Registry of New Interventional Procedures (SERNIP) of the Academy of 
Medical Royal Colleges. The history of SERNIP is described below along with a list of the 
procedures it has considered. 
 
It has a small staff and resources and yet has reviewed a wide range of procedures. These 
resource constraints, along with the desire to be independent of Government/NHS, have 
meant that the communication of its findings (and indeed, its existence) has not been as 
effective. It was apparent in 1998 that many Trust Medical Directors and Directors of Public 
Health were not aware of SERNIP's activity. 
 
The establishment of SERNIP predates the advent of Clinical Governance. Whilst the 
trigger for Clinical Governance was concern over the delivery of established procedures, 
some of the principles of Clinical Governance are anticipated by SERNIP. Indeed, it could 
be argued that unproven/experimental procedures represent a greater potential threat to 
patients than sub-standard delivery of established interventions. Thus, the importance of 
SERNIP has increased markedly and this should be reflected in its resources. 
 
Other bodies are responsible for establishing and maintaining registries of activity relating to 
individual procedures registered with SERNIP. In this case the Vascular Surgical Society of 
Great Britain and Ireland (VSSGBI) has been running the Registry for Endovascular 
Treatment of Aneurysms (RETA). Whilst this extensive database has been successfully 
managed (and resourced) by the VSSGBI, it has been more difficult for individual Trusts to 
find the resources to collect the large dataset; this has resulted in the incomplete 
registration of procedures. If decisions are to be made as to the future use of a procedure 
on the basis of incomplete datasets, then clearly there is considerable scope for major 
errors. It needs to be recognised that the implications of these registries for staff time may 
be as great as those required to participate in formal research. The NHS R&D Directorate 
and Academy of Medical Royal Colleges need to give this topic further consideration. 
 
Cross checks on unregistered cases could be made, e.g. by Trust medical supplies 
departments keeping records of devices and sharing the data with the relevant registry. 
Also, manufacturers could be asked to supply similar information, though they may view this 
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as problematic, compromising commercial confidentiality. The Medical Devices Agency 
should be asked to consider the problem. 
 
SERNIP 
 
Introduction 
 
In 1993, the Medical Royal Colleges, the Department of Health and the Government were 
increasingly aware of serious complications and even deaths resulting from what was 
becoming known as 'keyhole surgery'.  The Cabinet Advisory Committee on Science and 
Technology (ACOST) in a report on  'Medical Research and Health', was critical of the lack 
of a formal system for gathering information on new procedures and for ensuring that there 
was a systematic assessment of their safety and efficacy. 
 
The response has been to set up SERNIP in the Academy of Medical Royal Colleges to  
register new  interventions  and  act as an 'intelligence centre' co-ordinating the experiences 
of doctors developing new techniques and advising on the need for further research.  Being 
a professional organisation, rather than a government body, it aims to work with medical 
innovators and instrument suppliers to encourage new developments to a point where they 
can be shown to be safe and efficacious.  It does not attempt to evaluate 'effectiveness' in 
general use (that is the role of audit) nor economic issues (such as cost-benefit). 
 
The First Year of SERNIP 
 
An office was opened at the Academy of Medical Royal Colleges in May 1996 and an 
Executive Secretary was appointed to promote links with individual Colleges, specialty 
organisations, and the various tiers of the NHS R&D Executive. 
 
The Clinical Director took up office in October 1996 and following widespread consultations, 
established a central place for SERNIP within the global medical community; practitioners, 
providers, purchasers, research and development, health technology assessment and audit.  
One particularly fruitful exercise was to recruit the assistance of Local Research Ethics 
Committees in notifying new procedures to SERNIP. 
 
The Academy appointed Professor Norman MacKay to chair an Advisory Committee 
consisting of representatives nominated by those Royal Colleges with an interest in 
SERNIP’s initial remit (surgery, gynaecology, radiology and cardiology).  The Committee’s 
 51 
inaugural meeting was held in January 1997 and the draft constitution and minutes were 
presented to the Academy in February. Issues such as ‘safety’, ‘efficacy’ and ‘new 
procedures’ proved difficult to define in scientific terms, but pragmatic guidelines were 
proposed to enable the Committee to consider a number of novel interventions.  The current 
Chairman is Professor A G D Maran, President of the Royal College of Surgeons, 
Edinburgh. 
 
How SERNIP Works 
 
Researchers notify SERNIP of a new technique, citing any published results. SERNIP 
conducts a search of the Medline and Embase databases and looks for reviews in the 
Cochrane Library and the many international sources which are available on the Internet. 
This allows a synthesis to be made of  information on the subject, accepting  only  the 
hardest  scientific  evidence and  peer-reviewed papers  in  recognised journals. Personal 
reviews, conference proceedings and trade publications are not normally acceptable. 
 
They also liaise with the Medical Devices Agency, Medical Research Council, Centre for  
Reviews and Dissemination, National Co-ordinating Centre for Health Technology 
Assessment and others. 
 
This synthesis is then submitted to an Advisory Committee of experts nominated by the 
Royal Colleges who allocate the procedure to one of four categories: 
 
A. Safety and efficacy established, procedure may be used. 
 
B. Sufficiently close to a procedure of established safety and efficacy to give no 
reasonable grounds for questioning safety and/or efficacy; procedure may be used. 
 
C.    Safety and/or efficacy not yet established; procedure requires a fully controlled   
evaluation and may be used only as part of systematic research: 
i. an observational study in which all interventions and their outcomes are 
systematically recorded; 
ii.  a randomised controlled trial. 
 
D Safety and/or efficacy shown to be unsatisfactory; procedure should not be used. 
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SERNIP has so far evaluated 76 procedures of which:  
 
22 were in category 'A',   
10 in 'B',  
42 in 'C'  
  2 in 'D'. 
 
The 'C' Category 
 
Two-thirds of the procedures so far considered fall within this group. It implies that there are  
insufficient  data  to  prove,  with reasonable scientific confidence, that the procedure is safe 
or that  it  achieves  what  it  claims  (whether  diagnostic  or therapeutic)  and that further 
systematic clinical trials are required. 
 
SERNIP then tries to identify one key researcher who will co-ordinate the necessary trials 
and leaves that person to recruit others to the study: all should work to a standard protocol 
and collect the same data, leading to a publication.  When the results are accepted for 
publication in a recognised journal, SERNIP will reconsider the procedure and hopefully 
approve it for general use. 
 
During this development phase, SERNIP might receive enquiries from a health authority or 
Commissioning Group or Health Insurer as to whether the procedure had been approved.   
In the case of a 'C' procedure, it would be able to identify those units which were involved in 
the developmental studies and by implication offer the reassurance that no serious risks had 
been identified and that the procedure was being employed in a controlled fashion by the 
workers involved.  In other words, it would be sending a signal that it would be appropriate 
to 'purchase' the procedure from one of the known investigating centres.  Conversely, it 
could not send the same message about a unit which it did not know to be involved in the 
research project. 
 
Another aspect of the 'C' category relates to research funding. SERNIP hopes that Regional 
Research and Development Committees and other funding organisations will come to 
recognise that in awarding a grade 'C' to a procedure, SERNIP, as a responsible medical 
organisation, has scrutinised it and made a positive recommendation to proceed with 
research. 
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The Lessons 
 
Evidence-Based Medicine is here to stay and innovators will, in future, be expected to 
produce first-grade scientific proof of safety and efficacy. 
 
A procedure of unproven safety and/or efficacy should not be provided outside the clinical 
trial environment. 
 
There may be medico-legal implications to practising new interventional procedures outside 
a recognised and approved research programme. 
 
Help is at hand with regard to funding for research and development once a SERNIP 
category 'C' is awarded. 
 
The medical device industry is aware of the need to progress to an 'A category in order to 
maximise sales potential; manufacturers and suppliers will have to follow the pharmaceutical  
companies  by promoting and supporting  the necessary research. 
 
Co-operation with SERNIP is at present entirely voluntary, but if the profession decides to 
ignore the opportunity of being co-ordinated and advised by its own (in the form of the 
Medical Royal Colleges); it is more than likely that some form of statutory regulation system 
will emerge. 
 
How to Contact SERNIP 
 
The SERNIP office is situated at the  Academy of Medical Royal Colleges, 1 Wimpole 
Street, London, W1M, 8AE 
Tel: 0171 290 3917 
Fax: 0171 495 2432 
Email: nicoletaub@sernip.demon .co.uk 
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SERNIP CATEGORISATION OF PROCEDURES -  
from January 1997 to April 1999 
 
Serial No. Category A 
108 Angioplasty of pulmonary artery (balloon) 
54 Antireflux fundoplication using laparoscopic approach 
25 Embolisation of intracranial arteriovenous malformation 
6 Endovascular obiliteration of intracranial aneurysm (balloon) 
30 Extracorporeal membrane oxygenation (neonatal) 
33 Falloposcopy (linear eversion catheter) 
92 Injection of drug into vitreous (Ganciclovir implant) 
41 Intraoperative lymphatic mapping  
44 Laparoscopic adrenalectomy 
53 Laparoscopic closure of perforated duodenum 
52 Laparoscopic splenectomy 
120 Laser coagulation of ciliary body (endoscopic, diode laser) 
17 Laser coagulation of ciliary body (transscleral, diode laser) 
105 Peranal excision of lesion of rectum (transanal endoscopic microsurgery) 
11 Percutaneous emolisation of coronary artery fistula (coil) 
84 Simultaneous pancreas-kidney transplantation 
70 Stereotactic ablation of globus pallidus tissue (pallidotomy) 
95 Stereotactic ablation of thalamus tissue (thalamotomy) 
34 Stereotactic radiosurgery for intracranial arteriovenous malformations 
96 Therapeutic selective salpingography: cornual cannulation 
98 Therapeutic selective salpingography: tubal cannulation 
110 Transperineal prostate brachytherapy 
116 Uterotubal constrast sonography 
Serial No. Category B 
119 Colonic stenting 
38 Embolisation of intracranial aneurysm (Guglielmi coil) 
24 Endoscopic stapling of pharyngeal pouch 
46 Laparoscopic gastroplasty (Lap-Band) 
63 Mesh plug repair of inguinal hernia (PerFix) 
69 Pallidal deep brain stimulation (Parkinson disease) 
107 Percutaneous transintimal arterial recanalisation 
94 Thalamic deep brain stimulation (Parkinson disease) 
101 Thermal endometrial ablation (Gynecare) 
102 Thermal endometrial ablation (Vesta DUB) 
117 Vagus nerve stimulation for intractable partial seizures in adults 
 
NB: 
Intra-operative lymphatic mapping 
**approval of this procedure does not imply that sentinel node excision is a proven 
satisfactory alternative to level 2 axillary node dissection in breast cancer 
 
Serial No. Category Ci 
20 Embolisation of uterine artery (fibroids) 
121 Endovascular obliteration of intracranial arteriovenous malformation (Guglielmi coil) 
49 Excision of pelvic lymph nodes group (laparoscopic) 
28 Extracorporeal membrane oxygenation  (postneonatal paediatric) 
32 Falloposcopy (coaxial catheter) 
71 Islet cell transplant 
43 Laparo-endogastric surgery 
65 Microwave endometrial ablation 
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67 Non-surgical reduction of ventricular septum 
10 Percutaneous prosthetric closure of atrial septal defect (Amplatzer) 
109 Percutaneous prosthetric closure of atrial septal defect (ASDOS) 
76 Percutaneous vertebroplasty (methyl methacrylate) 
79 Pseudomyxoma peritonei (Sugarbaker technique) 
50 Pyeloplasty (laparoscopic) 
51 Radical laparoscopic hysterectomy 
58 Removal of cardiac pacing electrode (laser sheath) 
83 Selective peripheral denervation for cervical dystonia (torticollis) 
87 Stent placement in the right ventricular outflow tract 
89 Subthalamic nuclear stimulation (Parkinson's disease) 
90 Subthalamic nucleotomy (Parkinson's disease) 
99 Thermal endometrial ablation (Cavaterm) 
122 Vagus nerve stimulation for refractory epilepsy in children 
Serial No. Category Cii 
26 Abdominal aortic aneurysm stenting 
5 Autologous chondrocyte implantation of femoral condyle (Carticel) 
106 Circular stapling haemorrhoidectomy 
45 Colposuspension (laparoscopic) 
16 Cystourethropexy (In-tac) 
72 Cystourethropexy (Vesica) 
21 Endoscopic axillary lymph node retrieval 
22 Endoscopic dacryocystorhinostomy (laser) 
77 Endoscopic macroplastique injection outlet of female bladder 
47 Endoscopic primary repair of inguinal hernia (transperitoneal) 
29 Extracorporeal membrane oxygenation (adult) 
31 Extracorporeal photopheresis (systemic sclerosis) 
82 Implantation neurostimulator electrode spinal nerve root (sacral) - urge incontinence 
8 Insertion of carotid artery stent 
56 Laparoscopic simple nephrectomy (transperitoneal) 
75 Laser discectomy (lumbar) 
60 Partial left ventriculectomy (Batista) 
104 Splanchnic surgical sympathectomy (thoracoscopic) 
55 Total laparoscopic hysterectomy 
93 Viscosupplementation for osteoarthritis of knee (Synvisc) 
Serial No. Category D 
40 Intraoperative blood salvage (Haemocell 350) 
97 Therapeutic selective salpingography: guide-wire 
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SERNIP - CLASSIFICATION OF PROCEDURES 
 
 
a.  Safety and efficacy established; procedure may be used; 
 
b. Sufficiently close to an established procedure to give no reasonable grounds for 
questioning safety and efficacy; procedure may be used subject to continuing audit; 
 
ci. safety and/or efficacy not yet established; procedure requires a fully controlled 
evaluation and may be used only as part of systematic research, consisting of an 
observational study in which all interventions and their outcomes are systematically 
recorded; 
 
cii. Safety and/or efficacy not yet established; procedure requires a fully controlled 
evaluation and may be used only as part of systematic research, consisting of a 
randomised controlled trial and advise the Standing Group on Health Technology 
accordingly; 
   
d. Safety and/or efficacy shown to be unsatisfactory; procedure should not be used. 
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APPENDIX B   The Medical Devices Agency (MDA) 
 
Within the Medical Devices Agency (MDA), European and Regulatory Affairs (ERA) is 
responsible for the Agency's regulatory role as the UK's Competent Authority for the 
European Union Medical Devices Regulations.  ERA is implementing and enforcing the 
Medical Devices and the Active Implantable Medical Devices Regulations, and, in due 
course, the In Vitro Diagnostic (IVD) Directive. ERA appoints and audits Notified Bodies and 
assesses manufacturers' protocols for clinical investigations with the support of the MDA 
clinical team. It also issues regular Bulletins on aspects of the new unified regulatory 
European system and gives advice on other Directives which affect medical devices. 
 
All medical devices in order to be placed on the European market must now carry a C.E. 
marking (Conformité European). This indicates that the device in question has 
demonstrated compliance with a number of relevant essential requirements covering safety 
and performance. Unlike pharmaceutical products, where the Medicines Control Agency is 
responsible for assessing any pharmaceutical product and its suitability for use right up to 
the time of placing on the market, placing on the market for medical devices is under the 
control of third party accreditation bodies known as 'Notified Bodies'. Examples in the UK 
are BSI and Lloyds of London. A device manufactured and used within a Trust (i.e. by a 
member of staff) would not be subject to the Regulations. However, if such a device were 
given (even if free of charge) for use by a clinician in another Trust, it would be subject to 
the Regulations; the same would be true if manufactured in a University (e.g. its 
bioengineering department) for use in an NHS Trust. 
 
The MDA does not carry out, commission or consider formal effectiveness studies or cost-
effectiveness appraisals. The MDA’s role cannot be compared directly with that of the 
Medicines Control Agency (MCA), responsible for licensing drugs, as its assessment 
processes are less structured and its coverage is not comprehensive. 
 
The MDA also has a role similar to the CSM (Committee on Safety of Medicines) in that the 
MDA is also responsible for the investigation of device-related adverse incidents reported to 
it by users or by manufacturers. Such investigations may lead to the issuing of advice to the 
Health Service in the form of Safety or Hazard Notices, or in some cases even modification 
or recall of the product in question. 
 
MDA has close contacts with both SERNIP and MCIG (Managing Clinical Innovations 
Group) that supports NICE. 
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APPENDIX C Implications for Clinical Governance 
 
Clinical Governance in the NHS has been implemented in response to the concerns raised 
by the problems in Bristol in respect of paediatric cardiac surgery. These problems related 
to the delivery of well established interventions. These interventions had been the subject of 
data collection for audit purposes as part of a national cardiothoracic audit programme, 
which permitted valid comparisons to be made. 
 
The introduction of new procedures in any Trust has, at least until the advent of SERNIP, 
been subject to no systematic mechanisms. Yet the risks to patients (and the Trust) may be 
substantial. In addition, the ethical issues are more extreme than for standard research. In 
particular, informed consent is problematic in the absence (certainly at the start) of 
information and when the choices available to patients are stark. Because of the small 
numbers of patients likely to be subject to any such intervention in any one Trust, it is 
unlikely that valid information can accrue from even a well constructed dataset. 
 
Local experience indicates the existence of only ad hoc processes which may involve an 
ethics committee (research or other) or simply a discussion with the Medical Director. 
 
It is recommended that: 
 
1. Trusts establish more structured processes for the consideration and introduction of 
experimental procedures including: 
 
1.1 Referral for consideration by an ethics committee, constituted appropriately 
to discuss the issues (e.g. high proportion of lay representation, given the 
likely paucity of medical information); 
1.2 Registration with SERNIP; 
1.3 Resource allocation for systematic data collection. 
 
2. The NHS R&D Directorate and/or Academy of Medical Royal Colleges draw up 
explicit guidelines on the introduction of experimental procedures, with particular 
reference to patient consent issues and registration with SERNIP, and establish the 
relevance to Clinical Governance. 
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3. These responses must address carefully the delicate balance between the rights of 
individual patients and the need to encourage innovation. 
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97/08 Working Group on Acute Purchasing: The Use of Growth Hormone in Adults   £5.00 
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 Treatment of Alzheimer’s Disease (1997) by FA Pitt, J Chilcott, P Golightly,   
 J Sykes, M Whittingham.  
  
97/10 Working Group on Acute Purchasing: The Use of Bone Anchored Hearing Aids   £10.00 
 (1997) by NJ Cooper, J Tomlinson and J Sutton.  
  
98/01 Working Group on Acute Purchasing: A Review of the Use of Current Atypical  
 Antipsychotics in the Treatment of Schizophrenia (1998) by S Beard, J Brewin,  
 C Packham, P Rowlands, P Golightly. 
£10.00 
  
98/02 Working Group on Acute Purchasing: Internal Fixation of Tibial Shaft and   
 Distal Radius Fractures in Adults (1998) by NW Calvert, P Triffit, S Johnstone,  
 RG Richards. 
£10.00 
  
98/04 Working Group on Acute Purchasing: The Effectiveness of High Dose 
Chemotherapy and Autologous Stem Cell Transplantation in the Treatment of 
Hodgkin’s Disease and Non-Hodgkin’s Lymphoma (1998) by S Beard, P Lorigan, 
A Simms, F Sampson. 
£10.00 
 
98/05 Working Group on Acute Purchasing:  Angiotensin-Converting Enzyme (ACE) 
Inhibitors in Heart Failure: Reducing Mortality and Costs to the NHS (1998) by NW 
Calvert, J Cornell, C Singleton. 
 
 
£10.00 
98/06 Working Group on Acute Purchasing The Use Of Ultrasound (Viability) Scans In 
Early Pregnancy Bleeding (1998) by NW Calvert, C Singleton, P Tromans. 
£10.00 
  
98/08 Working Group on Acute Purchasing: The Effectiveness of High Dose 
Chemotherapy with Autologous Stem Cell / Bone Marrow Transplantation in the 
Treatment of Multiple Myeloma (1998) by S Beard, F Sampson, E Vandenberghe 
and F Scott. 
£10.00 
  
98/10 Working Group on Acute Purchasing: Supplementary Document: The Use of 
Paclitaxel in the First Line Treatment of Ovarian Cancer (1998) by S Beard, 
 R Coleman, J Radford and J Tidy. 
 
£10.00 
98/11 Working Group on Acute Purchasing: The Use of Fluoridated School Milk in the 
Prevention of Dental Caries (1998) by NW Calvert and N Thomas. 
 
£10.00 
99/01 Working Group on Acute Purchasing: The Role of Antileukotrienes in the 
Treatment of Chronic Asthma (1999) by M Stevenson, R Richards, S Beard. 
 
£15.00 
99/02 Working Group on Acute Purchasing: Partial Hepatectomy for Liver Metastases 
(1999) by S Beard, M Holmes, A Majeed, C Price. 
 
£15.00 
99/03 Working Group on Acute Purchasing: A Review of the Use of Propentofylline in 
the Treatment of Dementia (1999) by J Chilcott, K Perrett, P Golightly, J Sykes 
and  
M Whittingham. 
 
£15.00 
99/04 Working Group on Acute Purchasing: The Use of Routine Anti-D prophylaxis 
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